Cargando…

Anti-Sclerostin Antibody Inhibits Internalization of Sclerostin and Sclerostin-Mediated Antagonism of Wnt/LRP6 Signaling

Sclerosteosis is a rare high bone mass disease that is caused by inactivating mutations in the SOST gene. Its gene product, Sclerostin, is a key negative regulator of bone formation and might therefore serve as a target for the anabolic treatment of osteoporosis. The exact molecular mechanism by whi...

Descripción completa

Detalles Bibliográficos
Autores principales:	van Dinther, Maarten, Zhang, Juan, Weidauer, Stella E., Boschert, Verena, Muth, Eva-Maria, Knappik, Achim, de Gorter, David J. J., van Kasteren, Puck B., Frisch, Christian, Mueller, Thomas D., ten Dijke, Peter
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2013
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3639248/ https://www.ncbi.nlm.nih.gov/pubmed/23638027 http://dx.doi.org/10.1371/journal.pone.0062295

Ejemplares similares

The sclerostin-neutralizing antibody AbD09097 recognizes an epitope adjacent to sclerostin's binding site for the Wnt co-receptor LRP6
por: Boschert, V., et al.
Publicado: (2016)

Mutational Analysis of Sclerostin Shows Importance of the Flexible Loop and the Cystine-Knot for Wnt-Signaling Inhibition
por: Boschert, Verena, et al.
Publicado: (2013)

Correction: Mutational Analysis of Sclerostin Shows Importance of the Flexible Loop and the Cystine-Knot for Wnt-Signaling Inhibition
por: Boschert, Verena, et al.
Publicado: (2014)

Sclerostin
por: Silverman, Stuart L.
Publicado: (2010)

Sclerostin inhibits Wnt signaling through tandem interaction with two LRP6 ectodomains
por: Kim, Jinuk, et al.
Publicado: (2020)

Sclerostin and Vascular Pathophysiology
por: Catalano, Antonino, et al.
Publicado: (2020)

Sclerostin and Cardiovascular Disease
por: Tobias, Jonathan H.
Publicado: (2023)

Conformational Dynamics of Sclerostin-LRP6 Complex Analyzed by HDX-MS
por: Jeong, Yejing, et al.
Publicado: (2021)

Serum sclerostin levels in osteoporotic fracture patients
por: Gorter, Erwin A., et al.
Publicado: (2022)

Sclerostin, Osteocytes, and Wnt Signaling in Pediatric Renal Osteodystrophy
por: Laster, Marciana, et al.
Publicado: (2023)

Author Correction: Sclerostin inhibits Wnt signaling through tandem interaction with two LRP6 ectodomains
por: Kim, Jinuk, et al.
Publicado: (2022)

Sclerostin Inhibition in the Management of Osteoporosis
por: Appelman-Dijkstra, Natasha M., et al.
Publicado: (2016)

The Role of Sclerostin in Bone Diseases
por: Vasiliadis, Elias S., et al.
Publicado: (2022)

Drug discovery of sclerostin inhibitors
por: Yu, Sifan, et al.
Publicado: (2022)

The Effect of Sclerostin and Monoclonal Sclerostin Antibody Romosozumab on Osteogenesis and Osteoclastogenesis Mediated by Periodontal Ligament Fibroblasts
por: Pigeaud, Karina E., et al.
Publicado: (2023)

Lrp4 Mediates Bone Homeostasis and Mechanotransduction through Interaction with Sclerostin In Vivo
por: Bullock, Whitney A., et al.
Publicado: (2019)

Sclerostin: Current Knowledge and Future Perspectives
por: Moester, M. J. C., et al.
Publicado: (2010)

How Accurate is Your Sclerostin Measurement? Comparison Between Three Commercially Available Sclerostin ELISA Kits
por: Piec, Isabelle, et al.
Publicado: (2016)

Sclerostin and occlusion: A brief review
por: Bansal, Pankaj, et al.
Publicado: (2015)

The Role of Sclerostin in Bone and Ectopic Calcification
por: De Maré, Annelies, et al.
Publicado: (2020)

Effects of sclerostin antibody on bone healing
por: Mihara, Atsushi, et al.
Publicado: (2021)

Antitumor Effect of Sclerostin against Osteosarcoma
por: Ideta, Hirokazu, et al.
Publicado: (2021)

Sclerostin: From Molecule to Clinical Biomarker
por: Omran, Ahmed, et al.
Publicado: (2022)

Positive and Negative Regulators of Sclerostin Expression
por: Iwamoto, Rina, et al.
Publicado: (2022)

Sclerostin as a Putative Myokine in Sarcopenia
por: Yi, Hyon-Seung
Publicado: (2022)

IL-1β contributes to the secretion of sclerostin by osteocytes and targeting sclerostin promotes spinal fusion at early stages
por: Jiang, Zengxin, et al.
Publicado: (2023)

Elevated Circulating Sclerostin Concentrations in Individuals With High Bone Mass, With and Without LRP5 Mutations
por: Gregson, Celia L., et al.
Publicado: (2014)

Alterations in sclerostin protein in lesions of equine osteochondrosis
por: Power, Jonathon, et al.
Publicado: (2014)

Dental and periodontal phenotype in sclerostin knockout mice
por: Kuchler, Ulrike, et al.
Publicado: (2014)

Circulating levels of sclerostin are associated with cardiovascular mortality
por: Novo-Rodríguez, Cristina, et al.
Publicado: (2018)

Sclerostin Modulation Holds Promise for Dental Indications
por: Hassan, Mohamed G., et al.
Publicado: (2018)

Sclerostin expression in trabecular bone is downregulated by osteoclasts
por: Koide, Masanori, et al.
Publicado: (2020)

Sclerostin and Osteocalcin: Candidate Bone-Produced Hormones
por: Wang, Jialiang S., et al.
Publicado: (2021)

Obesity and Bone Loss at Menopause: The Role of Sclerostin
por: Marzullo, Paolo, et al.
Publicado: (2021)

Sclerostin and Its Involvement in the Pathogenesis of Idiopathic Scoliosis
por: Vasiliadis, Elias S., et al.
Publicado: (2021)

Importance of Sclerostin as Bone-Muscle Mediator Crosstalk
por: Aryana, I Gusti Putu Suka, et al.
Publicado: (2022)

The Role of Sclerostin in Rheumatic Diseases: A Review
por: Jaśkiewicz, Łukasz, et al.
Publicado: (2023)

Sclerostin: clinical insights in muscle–bone crosstalk
por: Moretti, Antimo, et al.
Publicado: (2023)

Sclerostin Is an Osteocyte-expressed Negative Regulator of Bone Formation, But Not a Classical BMP Antagonist
por: van Bezooijen, Rutger L., et al.
Publicado: (2004)

Osteocytic Sclerostin Expression as an Indicator of Altered Bone Turnover
por: Huybrechts, Yentl, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_grlhg84vp2s2ppr9lj72et4l09